Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
NHL
MCID: LYM143
MIFTS: 72

Lymphoma, Non-Hodgkin, Familial (NHL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lymphoma, Non-Hodgkin, Familial

About this section

MalaCards integrated aliases for Lymphoma, Non-Hodgkin, Familial:

Name: Lymphoma, Non-Hodgkin, Familial 56 37 39
Non-Hodgkin Lymphoma 56 12 74 58 29 6 15
Lymphoma, Non-Hodgkin 56 13 43 71
Nhl 56 58 73
Lymphoma, Non-Hodgkin, Somatic 56
Lymphoma, Follicular, Somatic 56
Familial Non-Hodgkin Lymphoma 73
Non-Hodgkin Lymphoma; Nhl 56
Lymphoma Non-Hodgkins 54
Non-Hodgkin Lymphomas 15
Non-Hodgkins Lymphoma 17

Characteristics:

Orphanet epidemiological data:

58
non-hodgkin lymphoma
Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases Rare diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0060060
OMIM 56 605027
MeSH 43 D008228
ICD10 32 C85.7 C85.9
MESH via Orphanet 44 D008228
UMLS via Orphanet 72 C0024305
Orphanet 58 ORPHA547
UMLS 71 C0024305
Sources

Summaries for Lymphoma, Non-Hodgkin, Familial

About this section
UniProtKB/Swiss-Prot : 73 Familial non-Hodgkin lymphoma: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

MalaCards based summary : Lymphoma, Non-Hodgkin, Familial, also known as non-hodgkin lymphoma, is related to lymphoma, mucosa-associated lymphoid type and mantle cell lymphoma. An important gene associated with Lymphoma, Non-Hodgkin, Familial is CASP10 (Caspase 10), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Entecavir and Nitrous oxide have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are lymphoma and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.

Wikipedia : 74 Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except... more...

More information from OMIM: 605027
Sources

Related Diseases for Lymphoma, Non-Hodgkin, Familial

About this section

Diseases related to Lymphoma, Non-Hodgkin, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 982)
# Related Disease Score Top Affiliating Genes
1 lymphoma, mucosa-associated lymphoid type 35.0 TP53 TNFRSF8 PAX5 MYC IRF4 CCND1
2 mantle cell lymphoma 34.8 TP53 PIK3CA PAX5 MYC MS4A1 CSF3
3 reticulosarcoma 34.6 TNFRSF8 PAX5 MYC BCL6 B2M ALK
4 composite lymphoma 34.4 TNFRSF8 PAX5 BCL6
5 plasmablastic lymphoma 34.3 MYC MS4A1 BCL6
6 richter's syndrome 34.3 TP53 MYC IRF4
7 lymphoplasmacytic lymphoma 34.2 PAX5 MS4A1 IRF4 CCND1
8 lymphoma 34.1 TP53 TNFRSF8 RAD54B PIK3CA PAX5 NRAS
9 follicular lymphoma 1 33.9 BCL6 BCL10
10 burkitt lymphoma 33.7 TP53 TNFRSF8 PAX5 MYC MS4A1 IRF4
11 myeloma, multiple 33.6 TP53 TNFRSF8 PRF1 PAX5 NRAS MYC
12 lymphoma, hodgkin, classic 33.5 TNFRSF8 PAX5 MS4A1 IRF4 CSF3 BCL6
13 leukemia, acute myeloid 33.1 TP53 TNFRSF8 PAX5 NRAS MYC CSF3
14 leukemia 33.1 TP53 PAX5 NRAS MYC CCND1 BRAF
15 lymphoblastic lymphoma 33.1 TP53 TNFRSF8 PAX5 MYC BCL6
16 primary mediastinal large b-cell lymphoma 33.1 IRF4 BCL6
17 b-cell lymphoma 33.0 TP53 TNFRSF8 PAX5 MYC MS4A1 IRF4
18 diffuse large b-cell lymphoma 33.0 TP53 TNFRSF8 PAX5 MYC IRF4 CSF3
19 leukemia, chronic lymphocytic 33.0 TP53 TNFRSF8 PAX5 NRAS MYC MS4A1
20 cll/sll 32.9 TP53 PAX5 CCND1 BCL6
21 acquired immunodeficiency syndrome 32.9 TP53 MYC CCND1 BCL6 B2M
22 myelodysplastic syndrome 32.9 TP53 PRF1 NRAS MYC CSF3 B2M
23 t-cell leukemia 32.8 TP53 PIK3CA NRAS MYC IRF4 CCND1
24 central nervous system lymphoma 32.6 TP53 PAX5 MYC BCL6
25 follicular lymphoma 32.6 PAX5 MYC MS4A1 IRF4 CCND1 BCL6
26 lymphocytic leukemia 32.6 TP53 PAX5 MYC MS4A1 CCND1 BRAF
27 sarcoma 32.5 TP53 PIK3CA NRAS MYC CCND1 BRAF
28 hodgkin's lymphoma, lymphocytic-histiocytic predominance 32.5 TNFRSF8 BCL6
29 hematologic cancer 32.5 TP53 TNFRSF8 PAX5 MYC IRF4 CSF3
30 gastric lymphoma 32.5 TP53 IRF4 BCL6 BCL10
31 renal cell carcinoma, nonpapillary 32.4 TP53 PIK3CA NRAS CCND1 BRAF B2M
32 breast lymphoma 32.4 TNFRSF8 IRF4 BCL6 ALK
33 marginal zone b-cell lymphoma 32.4 TNFRSF8 PAX5 IRF4 CCND1 BCL6 BCL10
34 adenocarcinoma 32.4 TP53 PIK3CA MYC CCND1 BRAF ALK
35 adult t-cell leukemia 32.4 TP53 TNFRSF8 MYC IRF4
36 bone lymphoma 32.4 TNFRSF8 PAX5 BCL6
37 plasmacytoma 32.3 PAX5 MYC IRF4 CCND1 B2M
38 leukemia, chronic myeloid 32.3 TP53 NRAS MYC IRF4 CSF3 CCND1
39 glioblastoma multiforme 32.3 TP53 PIK3CA NRAS MYC CSF3 CCND1
40 testicular lymphoma 32.3 TNFRSF8 IRF4 BCL6
41 lymphoma aids related 32.3 MYC BCL6
42 peripheral t-cell lymphoma 32.3 TP53 TNFRSF8 PAX5 MS4A1 CCND1 BCL6
43 adult lymphoma 32.3 TNFRSF8 MYC IRF4 CSF3 BCL6 ALK
44 thyroid carcinoma 32.2 TP53 PIK3CA NRAS BRAF
45 pediatric lymphoma 32.2 TNFRSF8 MYC IRF4 BCL6 ALK
46 squamous cell carcinoma 32.2 TP53 PIK3CA MYC CCND1 BRAF
47 neuroblastoma 32.2 TP53 PIK3CA NRAS MYC CSF3 CCND1
48 histiocytosis 32.1 TNFRSF8 NRAS BRAF ALK
49 pancreatic adenocarcinoma 32.1 TP53 PIK3CA MYC CSF3 CCND1 BRAF
50 nodular lymphocyte predominant hodgkin lymphoma 32.0 TNFRSF8 PAX5 CCND1 BCL6

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin, Familial:



Diseases related to Lymphoma, Non-Hodgkin, Familial
Sources

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin, Familial

About this section

Human phenotypes related to Lymphoma, Non-Hodgkin, Familial:

31
# Description HPO Frequency HPO Source Accession
1 lymphoma 31 HP:0002665

Clinical features from OMIM:

605027

GenomeRNAi Phenotypes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 BCL10 RAD54B RAD54L TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 BCL10 BRAF CCND1 MYC RAD54B RAD54L

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin, Familial:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 B2M BCL10 BCL6 BRAF CCND1 IRF4
2 hematopoietic system MP:0005397 10.31 B2M BCL10 BCL6 BRAF CCND1 CSF3
3 endocrine/exocrine gland MP:0005379 10.23 ALK B2M BCL10 BCL6 BRAF CCND1
4 immune system MP:0005387 10.22 B2M BCL10 BCL6 BRAF CCND1 CSF3
5 growth/size/body region MP:0005378 10.21 ALK B2M BCL6 BRAF CCND1 IRF4
6 homeostasis/metabolism MP:0005376 10.21 ALK B2M BCL6 BRAF CCND1 IRF4
7 cardiovascular system MP:0005385 10.19 B2M BCL6 BRAF CCND1 MYC NRAS
8 integument MP:0010771 10 ALK B2M BCL6 BRAF CCND1 CSF3
9 mortality/aging MP:0010768 10 ALK B2M BCL10 BCL6 BRAF CCND1
10 neoplasm MP:0002006 9.7 ALK B2M BRAF CCND1 IRF4 MYC
11 pigmentation MP:0001186 9.02 ALK BRAF MYC NRAS TP53
Sources

Drugs & Therapeutics for Lymphoma, Non-Hodgkin, Familial

About this section

Drugs for Lymphoma, Non-Hodgkin, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 607)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
2
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
3
Nitric Oxide Approved Phase 4 10102-43-9 145068
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
Prilocaine Approved Phase 4 721-50-6 4906
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
8
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Dacarbazine Approved, Investigational Phase 4 4342-03-4 5351166
11
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
12
Epirubicin Approved Phase 4 56420-45-2 41867
13
Ribavirin Approved Phase 4 36791-04-5 37542
14
Pirarubicin Investigational Phase 4 72496-41-4
15
Fotemustine Investigational Phase 4 92118-27-9
16 Anesthetics, Inhalation Phase 4
17 Sodium Channel Blockers Phase 4
18 Lidocaine, Prilocaine Drug Combination Phase 4
19 Diuretics, Potassium Sparing Phase 4
20 Antihypertensive Agents Phase 4
21 Giapreza Phase 4
22 Angiotensin II Type 1 Receptor Blockers Phase 4
23 Angiotensin Receptor Antagonists Phase 4
24 Angiotensinogen Phase 4
25 Thymoglobulin Phase 4
26 Hematinics Phase 4
27 Epoetin alfa Phase 4 113427-24-0
28
Metronidazole Approved Phase 3 443-48-1 4173
29 Orange Approved Phase 3
30
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
31
Gemcitabine Approved Phase 3 95058-81-4 60750
32
Ondansetron Approved Phase 3 99614-02-5 4595
33
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
34
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
35
deoxycholic acid Approved Phase 3 83-44-3 222528
36
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
37
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
38
Dalteparin Approved Phase 3 9005-49-6
39
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
40
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
41
Piperacillin Approved Phase 3 66258-76-2 43672
42
Tazobactam Approved Phase 3 89786-04-9 123630
43
Vancomycin Approved Phase 3 1404-90-6 441141 14969
44
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
45
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
46
Acyclovir Approved Phase 3 59277-89-3 2022
47
Palivizumab Approved, Investigational Phase 3 188039-54-5
48
Captopril Approved Phase 3 62571-86-2 44093
49
Calcium carbonate Approved, Investigational Phase 3 471-34-1
50
Zoledronic Acid Approved Phase 3 118072-93-8 68740

Interventional clinical trials:

(show top 50) (show all 2104)
# Name Status NCT ID Phase Drugs
1 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
2 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
3 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
4 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
5 Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
6 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
7 Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
8 Evaluation of the Analgesy Using a Local Anesthetic (Lidocaine and Prolocaine) Eutectic Mixture and/or Nitric Oxide at 50% in Oxygen (Livopan®) in Pediatric Patients That During Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
9 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
10 A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens Completed NCT00090038 Phase 4 rituximab
11 A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
12 Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
13 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
14 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
15 A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
16 The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP Completed NCT00162955 Phase 4 Valsartan
17 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
18 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
19 A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Recruiting NCT01909934 Phase 4 brentuximab vedotin
20 Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma Recruiting NCT04083079 Phase 4 PEG-rhG-CSF;rhG-CSF
21 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Recruiting NCT03558412 Phase 4 Decitabine
22 The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. Recruiting NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
23 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
24 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti－human Thymoglobulin;Placebo
25 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
26 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Not yet recruiting NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
27 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
28 Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study Terminated NCT02717949 Phase 4 sofosbuvir/ledipasvir;sofosbuvir;Ribavirin
29 A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
30 A Pilot/Feasibility Study of Ledipasvir/Sofosbuvir as Treatment for Hepatitis C in Hematopoietic Cell Transplantation (HCT) Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
31 Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission Unknown status NCT00091676 Phase 3
32 A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma Unknown status NCT01570049 Phase 3 Bendamustine
33 A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL Unknown status NCT00129090 Phase 3 R-CHOEP 14 with 12x Rituximab
34 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
35 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
36 Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
37 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
38 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
39 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
40 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
41 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
42 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
43 A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab) Unknown status NCT00022685 Phase 3
44 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
45 A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3 Rituximab or Iodine I 131 Tositumomab Therapy
46 Treatment of Low-Grade Gastric Non-Hodgkin‘s Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study) Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
47 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
48 A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
49 A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
50 A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate

Search NIH Clinical Center for Lymphoma, Non-Hodgkin, Familial

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
bendamustine
Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cladribine
fludarabine
Fludarabine phosphate
Ifosfamide
Lomustine
mercaptopurine
pegaspargase
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vincristine
Vincristine Sulfate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Non-Hodgkin, Familial cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lymphoma, Non-Hodgkin, Familial:
StemEx, umbilical cord blood stem/progenitor cells for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Hematopoietic stem cells for treatment of non-Hodgkin's lymphoma
Blood stem cell transplantation for hematological diseases
Embryonic/Adult Cultured Cells Related to Lymphoma, Non-Hodgkin, Familial:
Peripheral blood-derived hematopoietic stem cells PMIDs: 21831743
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: lymphoma, non-hodgkin

Sources

Genetic Tests for Lymphoma, Non-Hodgkin, Familial

About this section

Genetic tests related to Lymphoma, Non-Hodgkin, Familial:

# Genetic test Affiliating Genes
1 Non-Hodgkin Lymphoma 29 BCL10 CASP10 PRF1 RAD54B RAD54L
Sources

Anatomical Context for Lymphoma, Non-Hodgkin, Familial

About this section

MalaCards organs/tissues related to Lymphoma, Non-Hodgkin, Familial:

40
B Cells, T Cells, Bone, Bone Marrow, Breast, Liver, Lymph Node
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin, Familial:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
Sources

Publications for Lymphoma, Non-Hodgkin, Familial

About this section

Articles related to Lymphoma, Non-Hodgkin, Familial:

(show top 50) (show all 11500)
# Title Authors PMID Year
1
Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. 54 61 6
12010812 2002
2
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. 61 56
21796119 2011
3
Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. 61 56
15811955 2005
4
A proportion of patients with lymphoma may harbor mutations of the perforin gene. 61 56
15728124 2005
5
A tumour suppressor network relying on the polyamine-hypusine axis. 56
22722845 2012
6
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. 56
21390126 2011
7
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. 56
20081860 2010
8
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 56
20054396 2010
9
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. 56
19412164 2009
10
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. 56
18323416 2008
11
BRAF mutations in non-Hodgkin's lymphoma. 6
14612909 2003
12
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 6
12960123 2003
13
Inactivating mutations of the caspase-10 gene in gastric cancer. 6
11973654 2002
14
Age of onset evidence for anticipation in familial non-Hodgkin's lymphoma. 56
10651726 2000
15
Mutations in the RAD54 recombination gene in primary cancers. 6
10362365 1999
16
Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. 6
10362364 1999
17
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. 6
1565144 1992
18
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 54 61
19965662 2010
19
Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop. 54 61
20038219 2010
20
An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males. 54 61
19897031 2010
21
Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma. 54 61
19821039 2010
22
Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. 54 61
19809881 2010
23
A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. 54 61
19748593 2010
24
Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. 54 61
20414345 2010
25
Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. 54 61
19917125 2009
26
Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma. 54 61
19751723 2009
27
Speckled-like pattern in the germinal center (SLIP-GC), a nuclear GTPase expressed in activation-induced deaminase-expressing lymphomas and germinal center B cells. 54 61
19734146 2009
28
Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma. 54 61
19396635 2009
29
Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement. 54 61
19811326 2009
30
[Genetic susceptibility of single nucleotide polymorphism in MGMT to non-Hodgkin lymphoma]. 54 61
19954624 2009
31
Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation. 54 61
19137297 2009
32
Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. 54 61
19834627 2009
33
Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. 54 61
19452252 2009
34
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. 54 61
19388933 2009
35
BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. 54 61
19258594 2009
36
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. 54 61
19383901 2009
37
FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. 54 61
19245433 2009
38
Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker. 54 61
19100628 2009
39
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. 54 61
19225536 2009
40
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. 54 61
18981293 2009
41
Targeting CD40 in Waldenström's macroglobulinemia. 54 61
19362983 2009
42
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. 54 61
19135941 2009
43
Expression of activation-induced cytidine deaminase in malignant lymphomas infiltrating the bone marrow. 54 61
18776814 2008
44
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. 54 61
18940680 2008
45
Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. 54 61
18546271 2008
46
Primary tracheal lymphoma causing respiratory failure. 54 61
18670314 2008
47
Serum CA125 and PSA concentrations in patients with lymphoma. 54 61
18654120 2008
48
Polymorphisms of human N-acetyltransferases and cancer risk. 54 61
18680472 2008
49
FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. 54 61
18474295 2008
50
Re: Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma, author response. 54 61
18212328 2008
Sources

Variations for Lymphoma, Non-Hodgkin, Familial

About this section

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

6 (show top 50) (show all 57) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RAD54L NM_003579.4(RAD54L):c.1331T>A (p.Val444Glu)SNV Pathogenic 6192 rs121908689 1:46738430-46738430 1:46272758-46272758
2 CASP10 NM_032976.3(CASP10):c.*327C>TSNV Pathogenic 7765 rs28936699 2:202074111-202074111 2:201209388-201209388
3 CASP10 NM_001230.5(CASP10):c.685-2146C>TSNV Pathogenic 7766 rs121909775 2:202070652-202070652 2:201205929-201205929
4 CASP10 NM_032976.3(CASP10):c.*128_*129insAinsertion Pathogenic 7767 rs398122800 2:202073912-202073913 2:201209189-201209190
5 NRAS NM_002524.5(NRAS):c.38G>A (p.Gly13Asp)SNV Pathogenic 13901 rs121434596 1:115258744-115258744 1:114716123-114716123
6 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)SNV Pathogenic 13970 rs121913357 7:140481403-140481403 7:140781603-140781603
7 BRAF NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala)SNV Pathogenic 13971 rs121913355 7:140481402-140481402 7:140781602-140781602
8 BRAF NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
9 B2M NM_004048.3(B2M):c.286G>A (p.Asp96Asn)SNV Pathogenic 31907 rs398122820 15:45007839-45007839 15:44715641-44715641
10 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
11 TP53 NM_000546.5(TP53):c.844C>T (p.Arg282Trp)SNV Pathogenic/Likely pathogenic 12364 rs28934574 17:7577094-7577094 17:7673776-7673776
12 NRAS NM_002524.5(NRAS):c.38G>T (p.Gly13Val)SNV Pathogenic/Likely pathogenic 375876 rs121434596 1:115258744-115258744 1:114716123-114716123
13 PIK3CA NM_006218.4(PIK3CA):c.1030G>A (p.Val344Met)SNV Pathogenic/Likely pathogenic 376498 rs1057519942 3:178921548-178921548 3:179203760-179203760
14 TP53 NM_000546.5(TP53):c.845G>C (p.Arg282Pro)SNV Pathogenic/Likely pathogenic 376659 rs730882008 17:7577093-7577093 17:7673775-7673775
15 NRAS NM_002524.5(NRAS):c.37G>C (p.Gly13Arg)SNV Pathogenic/Likely pathogenic 13899 rs121434595 1:115258745-115258745 1:114716124-114716124
16 TP53 NM_000546.5(TP53):c.722C>A (p.Ser241Tyr)SNV Likely pathogenic 376663 rs28934573 17:7577559-7577559 17:7674241-7674241
17 TP53 NM_000546.5(TP53):c.721T>C (p.Ser241Pro)SNV Likely pathogenic 376664 rs1057520002 17:7577560-7577560 17:7674242-7674242
18 TP53 NM_000546.5(TP53):c.721T>G (p.Ser241Ala)SNV Likely pathogenic 376665 rs1057520002 17:7577560-7577560 17:7674242-7674242
19 TP53 NM_000546.5(TP53):c.614A>G (p.Tyr205Cys)SNV Likely pathogenic 376681 rs1057520007 17:7578235-7578235 17:7674917-7674917
20 TP53 NM_000546.5(TP53):c.614A>T (p.Tyr205Phe)SNV Likely pathogenic 376682 rs1057520007 17:7578235-7578235 17:7674917-7674917
21 TP53 NM_000546.5(TP53):c.614A>C (p.Tyr205Ser)SNV Likely pathogenic 376683 rs1057520007 17:7578235-7578235 17:7674917-7674917
22 PIK3CA NM_006218.4(PIK3CA):c.1031T>C (p.Val344Ala)SNV Likely pathogenic 376499 rs1057519941 3:178921549-178921549 3:179203761-179203761
23 RHOA NM_001664.4(RHOA):c.13C>T (p.Arg5Trp)SNV Likely pathogenic 376519 rs1057519952 3:49413010-49413010 3:49375577-49375577
24 RHOA NM_001664.4(RHOA):c.14G>A (p.Arg5Gln)SNV Likely pathogenic 376520 rs1057519953 3:49413009-49413009 3:49375576-49375576
25 RHOA NM_001664.4(RHOA):c.14G>T (p.Arg5Leu)SNV Likely pathogenic 376521 rs1057519953 3:49413009-49413009 3:49375576-49375576
26 RHOA NM_001664.4(RHOA):c.125A>G (p.Tyr42Cys)SNV Likely pathogenic 376522 rs1057519954 3:49412898-49412898 3:49375465-49375465
27 RHOA NM_001664.4(RHOA):c.125A>C (p.Tyr42Ser)SNV Likely pathogenic 376523 rs1057519954 3:49412898-49412898 3:49375465-49375465
28 RHOA NM_001664.4(RHOA):c.125A>T (p.Tyr42Phe)SNV Likely pathogenic 376524 rs1057519954 3:49412898-49412898 3:49375465-49375465
29 MAP2K1 NM_002755.3(MAP2K1):c.171G>C (p.Lys57Asn)SNV Likely pathogenic 376174 rs869025608 15:66727455-66727455 15:66435117-66435117
30 EZH2 NM_004456.4(EZH2):c.1936T>A (p.Tyr646Asn)SNV Likely pathogenic 376217 rs267601395 7:148508728-148508728 7:148811636-148811636
31 EZH2 NM_004456.4(EZH2):c.1937A>C (p.Tyr646Ser)SNV Likely pathogenic 376218 rs267601394 7:148508727-148508727 7:148811635-148811635
32 MYC NM_002467.6(MYC):c.218C>T (p.Thr73Ile)SNV Likely pathogenic 376300 rs756091827 8:128750681-128750681 8:127738435-127738435
33 B2M NM_004048.3(B2M):c.3G>A (p.Met1Ile)SNV Likely pathogenic 376368 rs1057519877 15:45003747-45003747 15:44711549-44711549
34 B2M NM_004048.3(B2M):c.1A>G (p.Met1Val)SNV Likely pathogenic 376369 rs1023835002 15:45003745-45003745 15:44711547-44711547
35 B2M NM_004048.3(B2M):c.1A>T (p.Met1Leu)SNV Likely pathogenic 376370 rs1023835002 15:45003745-45003745 15:44711547-44711547
36 B2M NM_004048.3(B2M):c.2T>C (p.Met1Thr)SNV Likely pathogenic 376371 rs1057519879 15:45003746-45003746 15:44711548-44711548
37 B2M NM_004048.3(B2M):c.2T>G (p.Met1Arg)SNV Likely pathogenic 376372 rs1057519879 15:45003746-45003746 15:44711548-44711548
38 EZH2 NM_004456.4(EZH2):c.1922A>T (p.Glu641Val)SNV Likely pathogenic 376412 rs1057519894 7:148508742-148508742 7:148811650-148811650
39 EZH2 NM_004456.4(EZH2):c.1922A>C (p.Glu641Ala)SNV Likely pathogenic 376413 rs1057519894 7:148508742-148508742 7:148811650-148811650
40 MAP2K1 NM_002755.3(MAP2K1):c.170A>C (p.Lys57Thr)SNV Likely pathogenic 376448 rs1057519909 15:66727454-66727454 15:66435116-66435116
41 MYC NM_002467.6(MYC):c.217A>C (p.Thr73Pro)SNV Likely pathogenic 376458 rs750664148 8:128750680-128750680 8:127738434-127738434
42 MYC NM_002467.6(MYC):c.173C>T (p.Pro58Leu)SNV Likely pathogenic 376459 rs1057519918 8:128750636-128750636 8:127738390-127738390
43 PIK3CA NM_006218.4(PIK3CA):c.1031T>G (p.Val344Gly)SNV Likely pathogenic 376497 rs1057519941 3:178921549-178921549 3:179203761-179203761
44 TP53 NM_000546.5(TP53):c.722C>G (p.Ser241Cys)SNV Likely pathogenic 177791 rs28934573 17:7577559-7577559 17:7674241-7674241
45 TP53 NM_000546.5(TP53):c.722C>T (p.Ser241Phe)SNV Likely pathogenic 12359 rs28934573 17:7577559-7577559 17:7674241-7674241
46 EZH2 NM_004456.4(EZH2):c.1937A>T (p.Tyr646Phe)SNV Likely pathogenic 76768 rs267601394 7:148508727-148508727 7:148811635-148811635
47 EZH2 NM_004456.4(EZH2):c.1936T>C (p.Tyr646His)SNV Likely pathogenic 76769 rs267601395 7:148508728-148508728 7:148811636-148811636
48 TP53 NM_000546.5(TP53):c.845G>A (p.Arg282Gln)SNV Conflicting interpretations of pathogenicity 237956 rs730882008 17:7577093-7577093 17:7673775-7673775
49 MYD88 NM_002468.5(MYD88):c.755T>C (p.Leu252Pro)SNV Uncertain significance 37055 rs387907272 3:38182641-38182641 3:38141150-38141150
50 TP53 NM_000546.5(TP53):c.974G>T (p.Gly325Val)SNV Uncertain significance 12367 rs121912659 17:7576872-7576872 17:7673554-7673554

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

73
# Symbol AA change Variation ID SNP ID
1 BRAF p.Gly469Ala VAR_018620 rs121913355
2 BRAF p.Gly469Arg VAR_018622 rs121913357
3 BRAF p.Asp594Gly VAR_018624 rs121913338
4 CASP10 p.Ala414Val VAR_037430 rs28936699

Copy number variations for Lymphoma, Non-Hodgkin, Familial from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 164351 22 36286416 36295356 Translate CEP1 Non-Hodgkin''s lymphomas
Sources

Expression for Lymphoma, Non-Hodgkin, Familial

About this section
Search GEO for disease gene expression data for Lymphoma, Non-Hodgkin, Familial.
Sources

Pathways for Lymphoma, Non-Hodgkin, Familial

About this section

Pathways related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.02 TP53 TNFRSF8 PIK3CA NRAS MYC IRF4
2
ERK Signaling 63
Show member pathways
 13.83 TP53 TNFRSF8 NRAS MYC CSF3 CCND1
3
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.11 TP53 PIK3CA NRAS MYC CCND1 CASP10
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.01 TP53 TNFRSF8 PIK3CA NRAS MYC IRF4
5
PI3K-Akt signaling pathway 36
Show member pathways
 13 TP53 PIK3CA NRAS MYC CSF3 CCND1
6
Human cytomegalovirus infection 36
Show member pathways
 12.93 TP53 PIK3CA NRAS MYC CCND1 B2M
7
Endometrial cancer 36
Show member pathways
 12.86 TP53 PIK3CA NRAS MYC CCND1 BRAF
8
Measles 36
Show member pathways
 12.82 TP53 PIK3CA MYC CCND1 B2M
9
Pathways in cancer 36
12.82 TP53 PIK3CA NRAS MYC CCND1 BRAF
10
Gastric cancer 36
Show member pathways
 12.77 TP53 PIK3CA NRAS MYC CCND1 BRAF
11
Apoptosis Modulation and Signaling 1
Show member pathways
 12.76 TP53 PRF1 PIK3CA NRAS MYC IRF4
12
Glioma 36
Show member pathways
 12.68 TP53 PIK3CA NRAS CCND1 BRAF ALK
13
ErbB signaling pathway 1 36
Show member pathways
 12.62 TP53 PIK3CA NRAS MYC CCND1 BRAF
14
T cell receptor signaling pathway 36
Show member pathways
 12.61 PIK3CA NRAS IRF4 BCL10 ALK
15
NF-kappaB Signaling 4
12.57 TNFRSF8 PAX5 IRF4 BCL6 BCL10 B2M
16
MicroRNAs in cancer 36
12.53 TP53 PIK3CA NRAS MYC CCND1
17
Apoptosis Pathway 70
Show member pathways
 12.44 TP53 PIK3CA NRAS CASP10
18
Development ERBB-family signaling 22
Show member pathways
 12.43 TP53 PIK3CA NRAS MYC CASP10 BRAF
19
Development IGF-1 receptor signaling 22
Show member pathways
 12.39 TP53 PIK3CA MYC CCND1
20
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 12.35 PIK3CA MYC CSF3 CCND1
21
Viral carcinogenesis 36
12.3 TP53 PIK3CA NRAS CCND1
22
Transcriptional misregulation in cancer 36
12.26 TP53 PAX5 MYC BCL6
23
Colorectal Cancer Metastasis 63
12.19 TP53 MYC CCND1 BRAF
24
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.19 TP53 PIK3CA NRAS MYC CCND1 BRAF
25
Human T-cell leukemia virus 1 infection 36
12.19 TP53 PIK3CA NRAS MYC CCND1 B2M
26
mTOR Pathway 70
Show member pathways
 12.18 TP53 PIK3CA NRAS BRAF
27
Cellular senescence (KEGG) 36
12.17 TP53 PIK3CA NRAS MYC CCND1
28
NGF Pathway 63
Show member pathways
 12.14 TP53 NRAS MYC BRAF
29
Integrated Breast Cancer Pathway 1
12.14 TP53 RAD54L MYC CCND1 BRAF
30
Proteoglycans in cancer 36
12.11 TP53 PIK3CA NRAS MYC CCND1 BRAF
31
FoxO signaling pathway 36
Show member pathways
 12.03 PIK3CA NRAS CCND1 BRAF BCL6
32
Thyroid hormone signaling pathway 36
11.95 TP53 PIK3CA NRAS MYC CCND1
33
Small cell lung cancer 36
11.89 TP53 PIK3CA MYC CCND1
34
Interleukin-4 and 13 signaling 65
11.89 TP53 MYC IRF4 CCND1 BCL6
35
B cell receptor signaling pathway (KEGG) 1
Show member pathways
 11.89 PIK3CA NRAS MYC IRF4 BRAF BCL6
36
Glioblastoma Multiforme 63
11.85 TP53 NRAS MYC CCND1 BRAF
37
Retinoblastoma (RB) in Cancer 1
11.84 TP53 MYC CCND1
38
VEGF Pathway (Tocris) 60
Show member pathways
 11.83 PIK3CA NRAS CASP10 BRAF
39
C-MYB transcription factor network 1
11.79 PAX5 NRAS MYC CCND1
40
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.72 PIK3CA MYC BRAF
41
Central carbon metabolism in cancer 36
11.72 TP53 PIK3CA NRAS MYC
42
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.71 PRF1 PIK3CA MYC
43
Pathways Affected in Adenoid Cystic Carcinoma 1
11.7 TP53 PIK3CA MYC
44
IL4-mediated signaling events 1
11.67 PIK3CA IRF4 BCL6
45
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.66 PRF1 BRAF B2M
46
Signaling events mediated by focal adhesion kinase 1
11.6 PIK3CA CCND1 BRAF
47
Copper homeostasis 1
11.6 TP53 PIK3CA CCND1
48
Hepatitis C and Hepatocellular Carcinoma 1
11.56 TP53 MYC CCND1
49
B Cell Development Pathways 64
11.56 TNFRSF8 PAX5 MS4A1 BCL6
50
miRNAs involved in DNA damage response 1
11.55 TP53 MYC CCND1
Sources

GO Terms for Lymphoma, Non-Hodgkin, Familial

About this section

Biological processes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.67 PIK3CA CSF3 BRAF
2 regulation of apoptotic process GO:0042981 9.65 TP53 CASP10 BCL6 BCL10 ALK
3 interferon-gamma-mediated signaling pathway GO:0060333 9.63 TP53 IRF4 B2M
4 regulation of cell proliferation GO:0042127 9.62 TP53 BRAF BCL6 ALK
5 cellular response to drug GO:0035690 9.61 TP53 MYC BRAF
6 positive regulation of histone deacetylation GO:0031065 9.48 TP53 BCL6
7 cellular response to DNA damage stimulus GO:0006974 9.43 TP53 RAD54L RAD54B MYC CCND1 BCL6
8 mitotic G1 DNA damage checkpoint GO:0031571 9.4 TP53 CCND1
9 DNA strand renaturation GO:0000733 9.37 TP53 RAD54L
10 chromosome organization GO:0051276 9.33 TP53 RAD54L MYC
11 cytokine-mediated signaling pathway GO:0019221 9.17 TP53 PIK3CA MYC IRF4 CSF3 CCND1

Molecular functions related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 TP53 PRF1 BRAF BCL6 BCL10 B2M
2 protein binding GO:0005515 9.58 TP53 TNFRSF8 RAD54L RAD54B PRF1 PIK3CA
3 transcription factor binding GO:0008134 9.35 TP53 MYC IRF4 CCND1 BCL10
4 DNA translocase activity GO:0015616 9.16 RAD54L RAD54B
Sources

Sources for Lymphoma, Non-Hodgkin, Familial

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....